본문바로가기

No Subject Date

47
Wellmarker Bio signs MoU with Isogenica for the development of multiple therapeutic assets
2022-05-31
46
Wellmarker Bio acquires “Certification of Excellence in Employee Invention Promotion” and “Certificate of IP Management Enterprise”
2022-05-18
45
Wellmarker Bio’s Immunotherapy ‘WM-A1’ gets nominated for the government-led R&D support program
2022-05-12
44
Wellmarker Bio and Paik Hospital Ink MoU to develop personalized anticancer drug
2022-04-22
43
Wellmarker Bio Receives Ministry of Food and Drug Safety (MFDS) Approval to Initiate Phase 1 Study of ‘WM-S1-030’
2022-04-13
42
Wellmarker Bio launches ambitious strategy to achieve Top 50 global pharmaceutical status within 10 years
2022-02-08
41
Wellmarker Bio Announces its latest pipeline news at the Korea Bio Investment Conference 2021
2021-12-09
40
Wellmarker Bio Receives Grand Prize at the '7th Good Company Awards' for Three Consecutive Years
2021-11-19
39
Wellmarker Bio Announces Pipeline Updates
2021-10-22
38
Wellmarker Bio Announced Successful First Subject Dosed in Phase I Clinical Study of WM-S1-030 for Treatment for Colorectal Cancer and Progressive ...
2021-07-20
1 2 3 4 5